Structure via PubChem · Public domain (PubChem)
rucaparib
Sign in to saveAlso known as AG-014699, AG014699, AG14447, PF-01367338, Rubraca
Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is taken by mouth.
In the Vinony graph
Within Vinony's link graph, rucaparib is referenced by 283 other articles, and connects out to chemotherapy, tiazofurin and liver.
It sits within the topics Benzazepines, Cancer treatments and Chemical articles with multiple CAS registry numbers.
Its subject is documented across 10 Wikipedia language editions.
Key facts
- Drug.image
- Rucaparib.svg
- Drug.image_class
- skin-invert-image
- Drug.caption
- Above: molecular structure of rucaparib Below: 3D representation of a rucaparib molecule
- Drug.image2
- Rucaparib 3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Rubraca
- Drug.MedlinePlus
- a617002
- Drug.DailyMedID
- Rucaparib
- Drug.pregnancy_category
- Not recommended
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XK03
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- 30–45% (Tmax = 1.9 hours)
- Drug.protein_bound
- 70% (in vitro)
via Wikipedia infobox
Chemical data
- Formula
- C19H18FN3O
- Molecular weight
- 323.4 g/mol
- IUPAC name
- 6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2016
- Admin. routes
- oral
- Indications
- neoplasm, pancreatic carcinoma, Hereditary breast and ovarian cancer syndrome, mesothelioma
via ChEMBL · EBI
Research
773 papers- Rucaparib.2006
- Rucaparib or Physician's Choice in Metastatic Prostate Cancer.The New England journal of medicine · 2023
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
- Rucaparib: A Review in Ovarian Cancer.Targeted oncology · 2019
- Rucaparib.2012
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 323.143
- Has use
- medication
Show 7 more facts
- chemical formula
- C₁₉H₁₈FN₃O
- canonical SMILES
- CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=CC(=CC(=C34)N2)F
- World Health Organisation international non-proprietary name
- rucaparib
- NCI Thesaurus ID
- C137800
- subject has role
- PARP inhibitor
- physically interacts with
- Poly(ADP-ribose) polymerase 1
- Commons category
- Rucaparib
via Wikidata · CC0
~7 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Pharmacology
- Mechanism of action
- History
- Society and culture
- Legal status
- Research
- Clinical trials
- References
- External links
{{Infobox drug | image = Rucaparib.svg | image_class = skin-invert-image | alt = | caption = Above: molecular structure of rucaparib Below: 3D representation of a rucaparib molecule | image2 = Rucaparib 3D.png | image_class2 = bg-transparent | alt2 =
| pronounce = | tradename = Rubraca | Drugs.com = | MedlinePlus = a617002 | DailyMedID = Rucaparib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = Not recommended | routes_of_administration = By mouth | class = | ATC_prefix = L01 | ATC_suffix = XK03 | ATC_supplemental =
Excerpted from Wikipedia’s “rucaparib” article, available under the CC BY-SA 4.0 licence.
Available in 10 languages
via Wikidata sitelinks · CC0